Oncology · NSCLCTrial Updateclinicalmid-term

Study of Pembrolizumab Plus MK-1084 in NSCLC with KRAS G12C Mutations

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/31/2026, 12:31:20 PM

Assessment confidence: 84% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The ongoing trial of MK-1084 in combination with Pembrolizumab for NSCLC patients with KRAS G12C mutations could significantly impact treatment options in oncology. Positive trial results may lead to enhanced market positioning and influence clinical guidelines for targeted therapies in this patient population. Regulatory context from FDA (FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer) supports the near-term read. Assessment grounded in 10 ranked evidence items (8 high-relevance).

Strategic Assessment

Positive outcomes may enhance the competitive profile of MK-1084 and influence treatment guidelines for NSCLC. The strongest clinical anchor is A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cel (ClinicalTrials.gov), sub-indication match (lung cancer); mechanism alignment (kras). In lung cancer, 1 regulatory and 4 competitive items passed relevance filtering for Pembrolizumab.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sub-indication match (lung cancer); mechanism alignment (kras). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial. This trial could position MK-1084 as a significant option in the targeted therapy landscape for NSCLC, particularly for patients with KRAS mutations.

Regulatory Outlook

Regulatory risk is concentrated around FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer (FDA). If the trial demonstrates positive safety and efficacy results, it may prompt regulatory filings that could expedite approval processes for MK-1084 as a treatment option.

Key Risks

Elevated medium regulatory exposure for Pembrolizumab could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful outcomes could increase market share for MK-1084 and Pembrolizumab in the competitive landscape of NSCLC treatments, potentially leading to higher revenues.
Upside for Pembrolizumab may improve if A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cel (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).

What Would Change This Assessment

This becomes more urgent if Monitor trial results and safety data for MK-1084, as well as any potential regulatory filings based on outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
FDAhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Cancer Clinical Trial Eligibility Criteria: Laboratory Values
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cel
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Mechanism alignment (KRAS)
FDA document
View source
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
ClinicalTrials.govmedium relevance
Entity match (pembrolizumab)
FDA document
View source
A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Mechanism alignment (KRAS)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Mechanism alignment (KRAS)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Pfizer)
Phase II/III Trial of BL-B01D1 with Osimertinib in EGFR-mutant NSCLC Initiated
Humanexa Signalsmedium relevance
Sub-indication match (lung cancer)

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedhigh relevance
Sub-indication match (lung cancer); Entity match (pembrolizumab)
FDA document
View source
Reshaping immunotherapy sequencing strategy: equivalent survival with induction plus consolidation vs. consolidation-only strategy in unresectable stage III NSCLC.
PubMedhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
High-flow nasal cannula oxygenation in sedated endoscopy for high-risk obstructive sleep apnea patients: study protocol for a multicentre randomised controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of probiotics on humoral responses to COVID-19 vaccination in older adults: a randomized, placebo-controlled trial (PIRATES-COV study).
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Pembrolizumab

Commercial impact

medium

Successful outcomes could increase market share for MK-1084 and Pembrolizumab in the competitive landscape of NSCLC treatments, potentially leading to higher revenues.

Regulatory impact

medium

If the trial demonstrates positive safety and efficacy results, it may prompt regulatory filings that could expedite approval processes for MK-1084 as a treatment option.

What to watch

Monitor trial results and safety data for MK-1084, as well as any potential regulatory filings based on outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.